Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs Trade Desk Inc (TTD) Price & Performance

Charles River Laboratories Intl. IncTrade
Trade Desk IncTrade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs Trade Desk Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $285.91 (market cap $13.46B), while Trade Desk Inc trades at $13.36 (market cap $6.37B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 2.1× Trade Desk Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Trade Desk Inc nearer its low. Which is the better fit depends on your goals.

CRLTTD
Market Cap
$13.46B$6.37B
Sector
HealthTechnology
52-Week High
$282.00$55.36
52-Week Low
$145.57$13.39
Enterprise Value
$16.30B$5.32B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.

The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.

Trade Desk Inc

The Trade Desk (TTD) stock trades at $13.39, down 2.97% today and near 52-week lows after a sharp 90% decline from its 2024 peak. Recent Q2 2026 earnings missed expectations with 3% revenue growth and weak Q3 guidance, triggering analyst downgrades. Technical indicators are bearish, with support at $12. The company maintains strong profitability margins but faces growth deceleration and competitive pressures in digital advertising.

Outlook remains cautious due to execution gaps and macroeconomic headwinds. While valuations appear reasonable with a P/E of 16.14, near-term risks from revenue declines and advertiser pullbacks outweigh potential upside. Investors should monitor Q3 earnings for signs of stabilization before considering entry.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About Trade Desk Inc

The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.

Read more on TTD